Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
HealthDay News — For patients with a conventional indication for dual-chamber pacing, a dual-chamber leadless pacemaker system consisting of 2 devices implanted percutaneously in the right atrium and the right ventricle safely provides atrial pacing and reliable atrioventricular synchrony, according to a study published online May 20 in the New England Journal of Medicine.
Reinoud E. Knops, MD, PhD, from the Amsterdam University Medical Center, and colleagues conducted a prospective, multicenter, single-group study to examine the safety and performance of a dual-chamber leadless pacemaker system among patients with a conventional indication for dual-chamber pacing. Freedom from complications at 90 days was examined as the primary safety end point.
The researchers found that the implantation procedure was successful in 295 of 300 patients. Overall, 29 patients had 35 device- or procedure-related serious adverse events. The primary safety end point was met in 90.3% of patients, which exceeded the 78% performance goal. The first primary performance end point of a combination of adequate atrial capture threshold and sensing amplitude at 3 months was met in 90.2% of patients, exceeding the performance goal of 82.5%. None of the 21 patients with a P-wave amplitude of less than 1.0 mV required device revision for inadequate sensing. In 97.3% of the patients, at least 70% atrioventricular synchrony was achieved, exceeding the performance goal of 83%.
“The implantation procedure was successful in 295 patients (98.3%), and 3-month safety and performance results exceeded the prespecified boundaries for success,” the authors write.
Several authors disclosed ties to biopharmaceutical and medical device companies, including Abbott Medical, which funded the study.
Abstract/Full Text (subscription or payment may be required)
